Clinical Trials
17
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Phase II Study of Platinum/Etoposide Plus Ivonescimab as First-Line Treatment of Extensive-Stage Small Cell Lung Cancer
- Conditions
- Extensive Stage Lung Small Cell Cancer
- Interventions
- Drug: Ivonescimab 10 mg/kgDrug: Ivonescimab 20 mg/kg
- First Posted Date
- 2025-07-10
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 60
- Registration Number
- NCT07057791
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
- Conditions
- Non Small Cell Lung CancerEpidermal Growth Factor Receptor Gene MutationStage III Lung CancerStage IV Lung Cancer
- Interventions
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 538
- Registration Number
- NCT06538038
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Mercy Clinic Fort Smith Communities, Fort Smith, Arkansas, United States
🇺🇸Mercy Research, Fort Smith, Arkansas, United States
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
- Conditions
- Pleural MesotheliomaMesotheliomaMalignant Pleural Mesothelioma
- Interventions
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 214
- Registration Number
- NCT04334759
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 181
- Registration Number
- NCT03836209
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸University of California, San Francisco-Fresno (University Oncology Associates), Clovis, California, United States
🇺🇸UCLA, Los Angeles, California, United States
Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age
- Conditions
- Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2019-02-08
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 33
- Registration Number
- NCT03834688
- Locations
- 🇺🇸
Carle Cancer Center, Urbana, Illinois, United States
🇺🇸Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸St. Joseph Mercy Hospital Cancer Care Center, Ann Arbor, Michigan, United States
- Prev
- 1
- 2
- 3
- 4
- Next